Press Release

23
Oct

Dr. William Gannon Joins the Ichor Science Advisory Board.

Ichor Therapeutics, a pre-clinical biotechnology company located in Syracuse, NY focused on therapeutic interventions for age-related disease, is pleased to announce the addition of William E. Gannon, Jr., MD to the Ichor Science Advisory Board. Dr. Gannon will be advising Ichor on clinical development planning and FDA compliance. His background managing clinical trials and operations as well as the design

Read more

21
Sep

CNY research startup raises $3.2 million to develop treatment for vision loss

By Elizabeth Doran | edoran@syracuse.com  LAFAYETTE, NY Inside a laboratory tucked in the LaFayette hills south of Syracuse, a small biotech company is quietly developing drugs that may show promise to treat, prevent and possibly even reverse macular degeneration, a disease that’s a leading cause of vision loss. The new drug therapies being developed and tested are designed to work on

Read more

28
Aug

Methuselah Foundation Fellowship Award Winner Tackles Research in Macular Degeneration

Typically, a fellowship and participation in a research study to cure a major disease would occur years after completing undergrad, possibly even after earning a PhD. But Jennifer DeRosa is not a typical student.  As early as high school, DeRosa was already in the lab, conducting research in plant biotechnology at the College of Environmental Science and Forestry (SUNY-ESF) before

Read more

19
Jul

Ichor nabs $600,000 program investment and new partnerships in wake of company expansion and promising early results

Ichor nabs $600,000 program investment and new partnerships in wake of company expansion and promising early results   Ichor builds new partnerships and lands $600k investment for its Age-related Macular Degeneration (AMD) research initiative, which has shown positive early results. Age-related Macular Degeneration (AMD) is a presently incurable eye condition leading to partial loss of vision and affects as many

Read more

20
Jun

Dr. Bärbel Rohrer Joins Ichor Therapeutics’ Scientific Advisory Board

LaFayette, NY, June 20, 2016 –  Ichor Therapeutics, Inc a biotech contract research firm specializing in age-related diseases, adds Dr. Bärbel Rohrer to their scientific advisory board. Dr. Rohrer will assist with the design and execution of pivotal animal studies for Ichor’s therapeutic candidates for age-related macular degeneration. “Dr. Rohrer is an addition of incredible value to our advisory team.”

Read more

1
Mar

Ichor lands $1.35 million, attracts international investors

FOR IMMEDIATE RELEASE LaFayette, New York, March 2nd, 2016 Ichor Therapeutics, a local biotechnology company focusing on therapeutic interventions for age-related disease, receives $1.35 million in new funding — including $1 million from European investors — and begins a 4-fold expansion of research capabilities in LaFayette, NY to engage in FDA compliant pre-clinical research. Ichor was founded in 2013 by

Read more

8
Dec

Ichor Receives Grant from MF for New C60 Based Myeloid Leukemia Cancer Research

Ichor Therapeutics, Inc., is a pre-clinical biotechnology company that develops technologies to target age-related pathology. The company received $79,775 in grant funding from Methuselah Foundation in July, 2015, to develop a C60-based therapy for acute myeloid leukemia (AML). AML is a lethal blood cancer with only a 24% five-year survival rate. Ichor reports that short-term biodistribution studies have been completed,

Read more

7
Jul

Ichor awarded $80,000 grant for oncology research

LaFayette, NY (PRWEB) July 07, 2015 Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, announced today that it has received $79,775 in new grant funding from Methuselah Foundation, a 501(c)3 non-profit that funds regenerative medicine R&D. This news comes in response to pilot studies completed at Ichor during winter 2014-2015 where c60oo administration doubled

Read more

3
Jun

Ichor Open House July 11th, 2015 11:00 AM – 3:00 PM

LaFayette, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, has announced a community open house on July 11th, 2015, from 11:00 AM – 3:00 PM. The company relocated to its new site in November, 2014, and has been renovating the facility to support life science research, including a 625 sq ft clean room.

Read more

1
Feb

CenterState CEO seeds Ichor macular degeneration program with Grants for Growth

LaFayette, NY: Ichor Therapeutics, Inc., a pre-clinical biotechnology company that develops technologies to target age-related pathology, has received a $25,000 grant from CenterState CEO through its Grants for Growth program. Announced in CenterState CEO’s February 2015 Newsletter, this funding will be used to develop an enzyme augmentation therapy to treat age-related macular degeneration, the leading cause of blindness and vision

Read more